17 March 2023 in Hepatology
MSMohammad Shadab Siddiqui
+2
1 November 2015 in Ageing Research Reviews
5 July 2021 in Liver International
Background and Aims: Peroxisome proliferator‐activated receptor (PPAR)‐γ agonists decrease hepatic/visceral fat (VF) and improve necroinflammation despite subcutaneous (SC) fat weight‐gain. Understanding the impact of changes in VF, VF‐to‐SC fat distribution (VF/SC) and adiponectin (ADPN) levels in relation to histological improvement after weight‐loss or pioglitazone is relevant as novel PPAR‐γ agonists are being developed for treating non‐alcoholic steatohepatitis (NASH).Methods: Fifty‐five patients with NASH received a −500 kcal/d hypocaloric diet and were randomized (double‐blind) to pioglitazone (45 mg/d) or placebo for 6‐months. Before and after treatment patients underwent a liver biopsy and measurement of hepatic/peripheral glucose fluxes, hepatic/adipose tissue‐IR and, in 35 patients, hepatic and VF/SC‐fat was measured by magnetic resonance spectroscopy/imaging. Data were examined by multivariable statistical analyses combined with machine‐learning techniques (partial least square discriminant analysis [PLS‐DA]).Results: Both pioglitazone (despite weight‐gain) and placebo (if weight‐loss) reduced steatosis but only pioglitazone ameliorated necroinflammation. Using machine‐learning PLS‐DA showed that the treatment differences induced by a PPAR‐γ agonist vs placebo on metabolic variables and liver histology could be best explained by the increase in ADPN and a decrease in VF/SC, and to a lesser degree, improvement in oral glucose tolerance test‐glucose concentrations and ALT. Decrease in steatosis and disease activity score (ballooning plus lobular inflammation) kept a close relationship with an increase in ADPN (r = −.71 and r = −.44, P < .007, respectively) and reduction in VF/SC fat (r = .41 and r = .37, P < .03 respectively).Conclusions: Reduction in VF and improved VF/SC‐distribution, combined with an increase in ADPN, mediate the histological benefits of PPAR‐γ action, highlighting the central role of fat metabolism and its distribution on steatohepatitis disease activity in patients with NASH.
15 February 2024 in Clinical Gastroenterology and Hepatology
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (two in three) and MASH with fibrosis (one in five) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide (GLP) -1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fibrosis.
9 September 2020 in BMJ Case Reports
A 49-year-old woman, previously healthy, presented with recurrent fractures provoked by minimal trauma. She had sustained seven fractures over the previous 2 years. While she was an avid runner, her injuries were determined to be out of proportion to the degree of trauma. Initial evaluation, exploring the more common causes such as low bone density and abnormal vitamin D metabolism, was unremarkable. On repeat of the some of the tests, a low alkaline phosphatase (AP) was noted, which raised suspicion for hypophosphatasia (HPP), a rare cause of recurrent fractures. Subsequent workup revealed a low bone-specific AP and elevated vitamin B6. Subsequently, genetic testing confirmed the diagnosis of adult-onset HPP caused by a heterozygous mutation c.407G>A in the ALPL gene. Asfotase alfa was started; however, the patient developed an allergic reaction leading to the discontinuation of the drug.
11 February 2026 in The Journal of Clinical Endocrinology & Metabolism
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.